Knockdown of ALPK2 blocks development and progression of renal cell carcinoma.

[1]  Xiaojian Zhang,et al.  miR-4429 Inhibits Tumor Progression and Epithelial-Mesenchymal Transition Via Targeting CDK6 in Clear Cell Renal Cell Carcinoma. , 2019, Cancer biotherapy & radiopharmaceuticals.

[2]  Jia-nian Zhang,et al.  LINC01510 suppresses cell proliferation and invasion by inhibiting Wnt/β-catenin signaling in renal cell carcinoma. , 2018, Biochemical and biophysical research communications.

[3]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[4]  Xiaobo Huang,et al.  Overexpression of COPS3 promotes clear cell renal cell carcinoma progression via regulation of Phospho–AKT(Thr308), Cyclin D1 and Caspase–3 , 2018, Experimental cell research.

[5]  R. Moon,et al.  ALPK2 Promotes Cardiogenesis in Zebrafish and Human Pluripotent Stem Cells , 2018, iScience.

[6]  Jianjun Liu,et al.  Resveratrol inhibits proliferation, migration and invasion via Akt and ERK1/2 signaling pathways in renal cell carcinoma cells. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  Ke Chen,et al.  Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma , 2018, BMC Cancer.

[8]  Liang Cheng,et al.  Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology. , 2017, Critical reviews in oncology/hematology.

[9]  M. Fishman,et al.  Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer , 2017, Cancer.

[10]  M. Ellis,et al.  CDK4/6 inhibition triggers anti-tumor immunity , 2017, Nature.

[11]  R. Figlin,et al.  ONCONEPHROLOGY: Targeted therapies for renal cell carcinoma , 2017 .

[12]  M. Muramatsu,et al.  An Alpha-kinase 2 Gene Variant Disrupts Filamentous Actin Localization in the Surface Cells of Colorectal Cancer Spheroids. , 2017, Anticancer Research.

[13]  E. Jaimes,et al.  Renal cell carcinoma: new insights and challenges for a clinician scientist. , 2017, American journal of physiology. Renal physiology.

[14]  Shenhong Wu,et al.  New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy , 2017, Journal of Hematology & Oncology.

[15]  J. Diehl,et al.  Cyclin D1, cancer progression, and opportunities in cancer treatment , 2016, Journal of Molecular Medicine.

[16]  Cheng Luo,et al.  Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer. , 2016, Cancer cell.

[17]  M. Knowles,et al.  PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma , 2016, BMC Cancer.

[18]  V. Sexl,et al.  CDK6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation , 2016, Oncogene.

[19]  Ke Chen,et al.  miR‐490‐5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA , 2015, Biology of the cell.

[20]  Junnian Zheng,et al.  HCRP-1 regulates cell migration and invasion via EGFR-ERK mediated up-regulation of MMP-2 with prognostic significance in human renal cell carcinoma , 2015, Scientific Reports.

[21]  Zhiyong Gao,et al.  Downregulation of miR-19a exhibits inhibitory effects on metastatic renal cell carcinoma by targeting PIK3CA and inactivating Notch signaling in vitro. , 2015, Oncology reports.

[22]  Y. Daaka,et al.  Rap1GAP regulates renal cell carcinoma invasion. , 2012, Cancer letters.

[23]  M. Kuroki,et al.  ALPK2 is crucial for luminal apoptosis and DNA repair-related gene expression in a three-dimensional colonic-crypt model. , 2012, Anticancer research.

[24]  W. Rathmell,et al.  Recent updates in renal cell carcinoma , 2010, Current opinion in oncology.

[25]  M. Huynen,et al.  Cellular and Molecular Life Sciences REVIEW The alpha-kinase family: an exceptional branch on the protein kinase tree , 2022 .

[26]  D. Jacqmin,et al.  The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. , 2006, Cancer research.

[27]  V. Velculescu,et al.  Oncogenic Mutations of PIK3CA in Human Cancers , 2004, Cell cycle.

[28]  E. Wynder,et al.  The epidemiology of renal cell carcinoma. A second look , 1995, Cancer.

[29]  J. L. Griffin,et al.  The time sequence of early events in the fertilization of sea urchin eggs. I. The latent period and the cortical reaction. , 1958, Experimental cell research.

[30]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.